Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

v3.21.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

 

    As of March 31, 2021     Fair Value Measurements  
    Carrying     Fair     As of March 31, 2021  
    Amount     Value     Level 1     Level 2     Level 3  
                (unaudited)              
Liabilities:                              
Contingent consideration:                                        
Asuragen (1)   $ 2,175     $ 2,175     $ -     $       -     $ 2,175  
Other long-term liabilities:                                        
Warrant liability (2)     62       62                -       -       62  
    $ 2,237     $ 2,237     $ -     $ -     $ 2,237  

 

  13  
 

 

    As of December 31, 2020     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2020  
    Amount     Value     Level 1     Level 2     Level 3  
                               
Liabilities:                                        
Contingent consideration:                                        
Asuragen (1)   $ 2,216     $ 2,216     $        -     $           -     $ 2,216  
Other long-term liabilities:                                        
Warrant liability (2)     21       21       -       -       21  
    $ 2,237     $ 2,237     $ -     $ -     $ 2,237  

 

(1)(2) See Note 9, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

 

                      Cancellation     Adjustment        
                      of Obligation/     to Fair Value/        
    December 31, 2020     Payments     Accretion     Conversions Exercises     Mark to Market     March 31, 2021  
    (unaudited)  
Asuragen   $ 2,216     $ (119 )   $ 135     $            -     $          (57 )   $ 2,175  
                                                 
Underwriters Warrants     21       -       -       -       41       62  
    $ 2,237     $ (119 )   $ 135     $ -     $ (16 )   $ 2,237